Please use this identifier to cite or link to this item: https://doi.org/10.1038/s41375-020-0819-8
Title: Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma
Authors: Goldschmidt, Hartmut
Dimopoulos, Meletios A
Rajkumar, S Vincent
Weisel, Katja C
Moreau, Philippe
Chng, Wee-Joo 
Mikala, Gabor
Cavo, Michele
Ramasamy, Karthik
Suryanarayan, Kaveri
Teng, Zhaoyang
Labotka, Richard
Victoria Mateos, Maria
Keywords: Science & Technology
Life Sciences & Biomedicine
Oncology
Hematology
STEM-CELL TRANSPLANTATION
LENALIDOMIDE MAINTENANCE
DOUBLE-BLIND
THERAPY
BORTEZOMIB
Issue Date: 23-Apr-2020
Publisher: SPRINGERNATURE
Citation: Goldschmidt, Hartmut, Dimopoulos, Meletios A, Rajkumar, S Vincent, Weisel, Katja C, Moreau, Philippe, Chng, Wee-Joo, Mikala, Gabor, Cavo, Michele, Ramasamy, Karthik, Suryanarayan, Kaveri, Teng, Zhaoyang, Labotka, Richard, Victoria Mateos, Maria (2020-04-23). Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma. LEUKEMIA 34 (11) : 3019-3027. ScholarBank@NUS Repository. https://doi.org/10.1038/s41375-020-0819-8
Abstract: In the TOURMALINE-MM3 study, post-autologous stem cell transplantation maintenance therapy with the oral proteasome inhibitor ixazomib versus placebo significantly improved progression-free survival (PFS), with a favorable safety profile. With ixazomib versus placebo maintenance, deepening responses occurred in 139/302 (46%) versus 60/187 (32%) patients with very good partial response or partial response (VGPR/PR) at study entry (relative risk 1.41, P = 0.004), and median time to best confirmed deepened response was 19.9 versus 30.8 months (24-month rate: 54.2 versus 41.4%; hazard ratio (HR): 1.384; P = 0.0342). Median PFS in patients with VGPR/PR at study entry was 26.2 versus 18.5 months (HR: 0.636, P < 0.001) with ixazomib versus placebo; in a pooled analysis across arms, in patients with versus without deepening responses, the median PFS was not reached versus 15.9 months (HR: 0.245, P < 0.001). In patients with deepening responses, 24-month PFS rate was 77.4 versus 68.3% with ixazomib versus placebo (HR: 0.831; P = 0.466); in patients without deepening responses, median PFS was 17.9 versus 14.1 months (HR: 0.741; P = 0.028). These analyses demonstrate the significantly higher rate of deepening responses with ixazomib versus placebo maintenance and the association between deepening response and prolonged PFS.
Source Title: LEUKEMIA
URI: https://scholarbank.nus.edu.sg/handle/10635/229005
ISSN: 08876924
14765551
DOI: 10.1038/s41375-020-0819-8
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant mainte.pdfPublished version644.85 kBAdobe PDF

OPEN

PublishedView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.